TABLE 2.
Factors associated with the serologic response to the SARS‐CoV‐2 vaccine
| Variable | Univariant | Multivariant | ||
|---|---|---|---|---|
| OR (95% CI) | p | OR (95% CI) | p | |
| Age (increase by year) | 1.1 (0.9 –1.1) | 0.16 | ||
| Time since transplantation (increase by year) | 1.0 (0.9–1.1) | 0.86 | ||
| Immunosuppressive regimen (reference, without mycophenolate) | 0.07 (0.02–0.25) | 0.001 | 0.08 (0.02–0.29) | 0.001 |
| Mycophenolate dose (increase by mg) | 1.0 (1.0–1.0) | 0.001 | ||
| Tacrolimus trough concentration (increase by µg/L) | 0.9 (0.6–1.4) | 0.71 | ||
| Everolimus trough concentration (increase by µg/L) | 1.1 (0.4–3.1) | 0.84 | ||
| Leukocyte count (increase by 1 × 103/µL) | 1.0 (1.0–1.0) | 0.009 | ||
| Lymphocyte count (increase by 1 × 103/µL) | 1.0 (1.0–1.0) | 0.010 | 1.0 (1.0–1.0) | 0.046 |
| Ratio Le/Ly (increase by unit) | 0.7 (0.5–0.9) | 0.04 | ||
| Serum creatinine (increase by mg/dL) | 0.2 (0.1–0.6) | 0.004 | ||
Abbreviations: CI, confidence interval; Le/Ly, ratio leukocyte/lymphocyte; OR, odds ratio; SARS‐CoV‐2, severe acute respiratory syndrome coronavirus 2.